Saturday 17 October 2026 Export LAB’s income statement to Excel — free account

Standard BioTools Inc.

In the quarter to June 2026, revenue fell 7.62%, EPS grew 22.2%, free cash flow grew 52.8% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.63 0.03 −4.55%

Follow LAB

Alert me

Market cap: $258.5M
P/E: 2.9×
Fwd P/E: −11.5×
Dividend yield: —
F-score: 4/9
Altman Z: −0.82
Beneish M: −2.93
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 14.44

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	4	1	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 3.66%

Capital & Financial Ratios $m

Market Cap 258.47

Revenue 84.60

Net Income 84.91

Free Cash Flow (82.58)

Net Debt (476.42)

Current Ratio 9.10

Debt/Equity 0.00

P/E ratio 2.86

Fwd P/E (11.50)

P/S ratio 2.91

P/B ratio 0.46

Past 5Y EPS Growth —

This Y EPS Growth 33.33%

Next Y EPS Growth (60.00%)

Next Y revenue growth (3.32%)

Next 5Y EPS Growth 2.27%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 58.61%

10-year low 10-year high

P/B against its own 10 years 0.09%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	115	293	188	477
Receivables	20	15	13	16
Inventory	21	21	20	17
Other	—	43	228	—
	158	376	454	517

	2023	2024	2025	Q'26
Payables	9	5	5	10
ST’ Debt	5	—	—	—
Other	—	21	26	—
	109	66	108	57

Compound Annual Growth %

	10y	5y	3y
Sales	(2.92%)	(9.19%)	(4.49%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	13.96%	25.00%	22.68%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	21	20	—	—	—
’25	20	22	20	24	85
’24	46	22	22	1	91
’23	25	28	25	28	106
’22	27	19	26	27	98
’21	33	31	29	38	131
’20	28	26	40	45	138

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(47)	(10)	—	—	—
’25	(30)	(21)	(22)	(1)	(74)
’24	(62)	(39)	(28)	(14)	(143)
’23	(8)	(9)	(11)	(14)	(43)
’22	(16)	(30)	(25)	(19)	(89)
’21	(13)	(15)	(9)	(7)	(44)
’20	(4)	(3)	(5)	(4)	(15)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(47)	(11)	—	—	—
’25	(35)	(23)	(23)	(2)	(83)
’24	(63)	(41)	(30)	(17)	(152)
’23	(9)	(10)	(12)	(14)	(46)
’22	(16)	(31)	(26)	(20)	(93)
’21	(20)	(19)	(11)	(7)	(57)
’20	(5)	(3)	(5)	(14)	(28)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.33	(0.07)	—	—	—
’25	(0.07)	(0.09)	(0.09)	0.05	(0.20)
’24	(0.27)	(0.12)	(0.07)	(0.09)	(0.52)
’23	(0.21)	(0.22)	(0.27)	(0.25)	(0.94)
’22	(0.99)	(0.82)	(0.37)	(0.26)	(2.43)
’21	(0.25)	(0.23)	(0.18)	(0.12)	(0.78)
’20	(0.23)	(0.18)	(0.08)	(0.24)	(0.74)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4.31	2.52	4.65	2.12	1.17	3.59	0.92	1.16	1.21	0.92	Analyst estimates 2026–2028 Powerpack
	High	11.05	8.69	9.08	14.90	12.45	7.51	4.23	3.16	3.04	2.14
People
People	Employees	589	505	535	566	627	615	523	539	818	389
	Revenue/emp, $m	0.18	0.20	0.21	0.21	0.22	0.21	0.19	0.20	0.11	0.22
Income, $m
Income, $m	Revenue	104	102	113	117	138	131	98	106	91	85
	Gross margin, %	55.95	50.99	54.57	54.83	60.32	53.13	37.83	47.44	49.32	49.86
	EBT	(80)	(64)	(61)	(67)	(54)	(64)	(193)	(74)	(90)	(97)
	EBT margin, %	(76.76)	(62.59)	(54.37)	(56.89)	(39.16)	(48.75)	(196.97)	(69.78)	(99.33)	(113.33)
	Net income	(76)	(61)	(59)	(65)	(53)	(59)	(190)	(75)	(139)	(75)
	Depreciation	18	19	25	18	18	16	14	14	9	8
Per share, $
Per share, $	Revenue	3.60	3.09	2.85	1.76	1.92	1.72	1.25	1.34	0.26	0.22
	Earnings	(2.62)	(1.84)	(1.49)	(0.97)	(0.74)	(0.78)	(2.43)	(0.94)	(0.52)	(0.20)
	Cash flow	(1.35)	(0.73)	(0.64)	(0.53)	(0.21)	(0.58)	(1.14)	(0.55)	(0.41)	(0.19)
	Capex	(0.17)	(0.05)	(0.01)	(0.04)	(0.18)	(0.17)	(0.05)	(0.04)	(0.02)	(0.02)
	Free cash flow	(1.52)	(0.78)	(0.64)	(0.57)	(0.39)	(0.76)	(1.19)	(0.58)	(0.43)	(0.22)
	Book value	1.84	0.94	1.82	2.30	1.93	1.25	2.93	2.06	1.34	1.11
	Shares, m	29	33	40	67	72	76	78	79	353	382
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	2.11	2.02	3.03	1.98	3.13	2.28	1.04	1.65	6.79	5.72
	P/B	4.14	6.64	4.74	1.51	3.11	3.14	0.00	0.00	1.31	1.15
	EV/Sales	3.41	3.31	3.70	1.96	3.05	2.60	0.01	0.66	3.63	3.59
	EV/FCF	(6.99)	(10.46)	(13.01)	(5.17)	(12.12)	(5.31)	(0.01)	(1.32)	(2.09)	(3.43)
Cash, $m
Cash, $m	Operating cash flow	(39)	(24)	(25)	(35)	(15)	(44)	(89)	(43)	(143)	(74)
	Capex	(5)	(2)	0	(3)	(13)	(13)	(4)	(3)	(8)	(8)
	Free cash flow	(44)	(26)	(26)	(38)	(28)	(57)	(93)	(46)	(152)	(83)
Balance, $m
Balance, $m	Working capital	67	61	90	63	63	22	165	49	310	346
	Total debt	195	195	172	56	57	71	65	9	0	0
	Net debt	136	132	77	(3)	(11)	43	(101)	(106)	(293)	(187)
	Shareholders’ equity	53	31	72	154	139	95	230	163	472	424
Returns, %
Returns, %	ROA	(22.47)	(20.39)	(19.97)	(22.79)	(17.99)	(19.75)	(57.13)	(20.93)	(39.53)	(12.69)
	ROIC	(24.23)	(22.37)	(20.23)	(21.51)	(24.97)	(30.73)	(56.35)	(83.57)	(44.48)	(29.07)
	ROE	(90.39)	(143.84)	(114.53)	(57.41)	(36.23)	(50.71)	(2,895.83)	65.05	(114.25)	(16.72)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CLPT ClearPoint Neuro, Inc.	$294.1M	— (loss-making)	— (loss-making)	+18.07% (above 0%: growing)	n/m	−173.51% (below 0%: shrinking)	61.67%	(94.15%)	Compare
QSI Quantum-Si Incorporated	$286.7M	— (loss-making)	— (loss-making)	−41.79% (below 0%: shrinking)	n/m	+9.75% (above 0%: growing)	50.00%	(7,450.29%)	Compare
INFU InfuSystems Holdings, Inc.	$277.2M	31.7×	21.7×	+2.59% (above 0%: growing)	+33.33% (above 0%: growing)	−66.54% (below 0%: shrinking)	57.98%	11.24%	Compare
TMCI Treace Medical Concepts, Inc.	$267.9M	— (loss-making)	— (loss-making)	−4.24% (below 0%: shrinking)	n/m	+11.74% (above 0%: growing)	78.47%	(32.96%)	Compare
CATX Perspective Therapeutics, Inc.	$267.1M	— (loss-making)	— (loss-making)	−72.07% (below 0%: shrinking)	n/m	−66.09% (below 0%: shrinking)	100.00%	(36,120.99%)	Compare
LAB Standard BioTools Inc.	$258.5M	2.9×	— (loss-making)	−7.62% (below 0%: shrinking)	n/m	+52.76% (above 0%: growing)	52.40%	(126.28%)
TLSI TriSalus Life Sciences, Inc.	$240.1M	— (loss-making)	— (loss-making)	+1.73% (above 0%: growing)	n/m	−41.29% (below 0%: shrinking)	86.78%	(86.03%)	Compare
ELMD Electromed, Inc.	$232.3M	20.0×	25.5×	+11.64% (above 0%: growing)	+57.69% (above 0%: growing)	−25.15% (below 0%: shrinking)	78.71%	19.70%	Compare
PROF Profound Medical	$230.5M	— (loss-making)	— (loss-making)	+12.30% (above 0%: growing)	n/m	+17.51% (above 0%: growing)	78.41%	(445.67%)	Compare
Median of peers	$267.5M	—	—	+2.16%	—	−33.22%	78.44%	(90.09%)

All 149 Medical Devices stocks →

Standard BioTools Inc. (LAB) key facts

Standard BioTools Inc. (LAB) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LAB traded at $0.63, a market capitalization of $258.5 million.
Return on equity was −16.7% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −0.82 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.